JNJ Stock Surges on Strong Earnings and FDA Clearances

Johnson & Johnson (NYSE:JNJ) stock rose 3.3% during trading on Tuesday, reaching as high as $271.73 and closing at $271.0480.

The company's quarterly revenue increased by 6.6% year-over-year to $25.31 billion, exceeding analyst estimates of $25.06 billion.

J&J received FDA clearance for the AI-powered MONARCH QUEST 3 bronchoscopy system and its robotic surgical system, OTTAVA, has also been authorized by the FDA.

The company's FY 2026 guidance is set at $11.60 to $11.75 earnings per share, while analysts predict Johnson & Johnson will post $11.61 EPS for the current fiscal year.